Construction of administration algorithm of novel oral molecular-targeted anti-cancer drugs based on the clarificationof interindividual differences of pharmacokinetics and pharmacodynamics

基于药动学和药效学个体差异的阐明新型口服分子靶向抗癌药物给药流程的构建

• 批准号: 22390029
• 负责人: TERADA Tomohiro
• 金额: $ 11.56万
• 依托单位: Shiga University of Medical Science
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Scientific Research (B)
• 财政年份: 2010
• 资助国家: 日本
• 起止时间: 2010 至 2012
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-22390029/
• 关键词: 薬学; 癌; 薬剤反応性; 分子標的抗がん剤; がん

We carried out clinical pharmacological studies for three kinds of novel oral molecular-targeted anti-cancer drugs. It has been demonstrated that sorafenib can be used safely and effectively for the hemodialyzed patient. We have also provided evidences that Breast Cancer Resistant Protein expressed in the intestine plays pivotal roles for regulatory factors for pharmacokinetic characteristics of sunitinib.Furthermore, we reported that erlotinib can be administered safely to non-small-cell lung cancer patients of malignant pleural effusion with respect to efficacy and side effects. These findings may be useful information to drive the personalized medicine of novel oral molecular-targeted anti-cancer drugs

我们对三种新型口服分子靶向抗癌药物进行了临床药理研究。已经证明索拉非尼可以安全有效地用于血液透析患者。我们也提供了证据表明，在肠道中表达的乳腺癌耐药蛋白在舒尼替尼药代动力学特征的调节因子中起关键作用。此外，我们报道了厄洛替尼可以安全地用于非小细胞肺癌恶性胸腔积液患者的疗效和副作用。这些发现可能为推动新型口服分子靶向抗癌药物的个性化治疗提供有用的信息

项目成果

Renal Tubular Secretion of Varenicline by Multidrug and Toxin Extrusion (MATE) Transporters

• DOI: 10.2133/dmpk.dmpk-11-rg-156
• 发表时间: 2012-12-25
• 期刊: DRUG METABOLISM AND PHARMACOKINETICS
• 影响因子: 2.1
• 作者: Kajiwara, Moto;Masuda, Satohiro;Inui, Ken-ichi
• 通讯作者: Inui, Ken-ichi

がん領域におけるチーム医療と薬剤師の役割

团队医疗护理和药剂师在癌症领域的作用

• 发表时间: 2011
• 作者: 寺田智祐;森井博朗
• 通讯作者: 森井博朗

Role of pharmacists in the frontline of pharmacotherapy

药剂师在药物治疗第一线的作用

• 发表时间: 2011
• 作者: Terada;T.
• 通讯作者: T.

新規経口マルチキナーゼ阻害剤の体内動態とpharmacogenomics

新型口服多激酶抑制剂的药代动力学和药物基因组学

• 发表时间: 2011
• 作者: Terada;T.;寺田智祐
• 通讯作者: 寺田智祐

Reduced Renal Clearance of a Zwitterionic Substrate Cephalexin in Mate1-Deficient Mice

• DOI: 10.1124/jpet.110.169433
• 发表时间: 2010-08-10
• 期刊: JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
• 影响因子: 3.5
• 作者: Watanabe, Shingo;Tsuda, Masahiro;Inui, Ken-ichi
• 通讯作者: Inui, Ken-ichi